EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preclinical Evaluation of a Novel High-Affinity Radioligand [99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA)

Ekaterina Bezverkhniaia iD, Panagiotis Kanellopoulos iD, Ayman Abouzayed, Mariia Larkina iD, Maryam Oroujeni iD, Anzhelika Vorobyeva iD, Ulrika Rosenström iD, Vladimir Tolmachev iD, Anna Orlova iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms242417391 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Ekaterina Bezverkhniaia und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Uppsala University, 751 23 Uppsala, Sweden. Hauptthemen laut MEDLINE: Prostate, Prostatic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Cancer Society, Swedish Research Council, Uppsala University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radionuclide imaging using radiolabeled inhibitors of prostate-specific membrane antigen (PSMA) can be used for the staging of prostate cancer. Previously, we optimized the Glu-urea-Lys binding moiety using a linker structure containing 2-napththyl-L-alanine and L-tyrosine. We have now designed a molecule that contains mercaptoacetyl–triglutamate chelator for labeling with Tc-99m (designated as BQ0413). The purpose of this study was to evaluate the imaging properties of [99mTc]Tc-BQ0413. PSMA-transfected PC3-pip cells were used to evaluate the specificity and affinity of [99mTc]Tc-BQ0413 binding in vitro. PC3-pip tumor-bearing BALB/C nu/nu mice were used as an in vivo model. [99mTc]Tc-BQ0413 bound specifically to PC3-pip cells with an affinity of 33 ± 15 pM. In tumor-bearing mice, the tumor uptake of [99mTc]Tc-BQ0413 (38 ± 6 %IA/g in PC3-pip 3 h after the injection of 40 pmol) was dependent on PSMA expression (3 ± 2 %IA/g and 0.9 ± 0.3 %IA/g in PSMA-negative PC-3 and SKOV-3 tumors, respectively). We show that both unlabeled BQ0413 and the commonly used binder PSMA-11 enable the blocking of [99mTc]Tc-BQ0413 uptake in normal PSMA-expressing tissues without blocking the uptake in tumors. This resulted in an appreciable increase in tumor-to-organ ratios. At the same injected mass (5 nmol), the use of BQ0413 was more efficient in suppressing renal uptake than the use of PSMA-11. In conclusion, [99mTc]Tc-BQ0413 is a promising probe for the visualization of PSMA-positive lesions using single-photon emission computed tomography (SPECT).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProstateProstatic NeoplasmsMaleHumansAnimalsMiceMice, Inbred BALB CGlutamate Carboxypeptidase IIAntigens, SurfaceTechnetiumGallium Radioisotopes

Stichwörter der Autor:innen

BQ0413PSMAprostate cancerprostate-specific membrane antigensingle-photon emission computed tomographytechnetium-99m

Substanzen

Glutamate Carboxypeptidase IIAntigens, SurfaceTechnetiumPSMA-11Gallium Radioisotopes

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Uppsala University, 751 23 Uppsala, Sweden.
  • Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634009 Tomsk, Russia.
  • Scientific and Research Laboratory of Chemical and Pharmaceutical Research, Siberian State Medical University, 634050 Tomsk, Russia.
  • Department of Immunology, Genetics and Pathology, Uppsala University, 752 37 Uppsala, Sweden.
  • Affibody AB, 171 65 Solna, Sweden.
  • Science for Life Laboratory, Uppsala University, 752 37 Uppsala, Sweden.

ORCID-Profile: Ekaterina Bezverkhniaia, Panagiotis Kanellopoulos, Mariia Larkina, Maryam Oroujeni, Anzhelika Vorobyeva, Ulrika Rosenström, Vladimir Tolmachev, Anna Orlova

Förderung

  • Swedish Cancer Society
  • Swedish Research Council
  • Uppsala University
  • Tomsk Polytechnic University

Zitieren

APA

Bezverkhniaia, E., Kanellopoulos, P., Abouzayed, A., Larkina, M., Oroujeni, M., Vorobyeva, A., Rosenström, U., Tolmachev, V., & Orlova, A. (2023). Preclinical Evaluation of a Novel High-Affinity Radioligand [99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA). International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242417391

Vancouver

Bezverkhniaia E, Kanellopoulos P, Abouzayed A, Larkina M, Oroujeni M, Vorobyeva A, et al. Preclinical Evaluation of a Novel High-Affinity Radioligand [99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA). International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242417391

BibTeX
@article{Bezverkhniaia2023,
  author = {Bezverkhniaia, Ekaterina and Kanellopoulos, Panagiotis and Abouzayed, Ayman and Larkina, Mariia and Oroujeni, Maryam and Vorobyeva, Anzhelika and Rosenström, Ulrika and Tolmachev, Vladimir and Orlova, Anna},
  title = {Preclinical Evaluation of a Novel High-Affinity Radioligand [99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA)},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242417391}
}
Kostenlos starten →